A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.

Fuyuhiko MotoiSohei SatoiGoro HondaKeita WadaHiroyuki ShinchiIppei MatsumotoMasayuki ShoAkihiko TsuchidaMichiaki Unnonull null

Published in: Journal of gastroenterology (2018)

NAC-GS was feasible and actively prolonged survival following PDAC planned resection. Randomized control trials are needed to further clarify the survival benefit of NAC-GS in addition to surgery followed by adjuvant therapy.

Keyphrases

locally advanced
rectal cancer
transcription factor
open label
squamous cell carcinoma
minimally invasive
placebo controlled
radiation therapy
free survival
double blind
liver metastases
coronary artery bypass
men who have sex with men
phase iii
clinical trial
phase ii
surgical site infection